ecancermedicalscience

Review

Infracentimetric HER-2 positive breast tumours—review of the literature

18 Nov 2015
Danilo da Fonseca Reis Silva, Joana M Ribeiro

Breast cancer is the most common malignant neoplasm in the world among women. As a result of the dissemination of population screening programmes, about half of non-metastatic breast cancers are now diagnosed at stage I. 10–15% of T1abN0 tumours over-express human epidermal growth factor (HER-2). These tumours have a globally excellent prognosis, however, treatment with chemotherapy and/or targeted therapy may further improve outcomes in selected cases. In this article, we will review studies with information on prognosis and benefit of adjuvant therapy for T1abN0 HER-2 breast cancer.

Related Articles

Don Thiwanka Wijeratne, Christopher M Booth, Sanjeewa Seneviratne, Bishal Gyawali, Matt Jalink, Malinthi Soysa, Sachith Abhayaratna, Hasitha Promod, Punika Wijesinghe, Sanjeeva Gunasekera
Prasanth S Ariyannur, Reenu Anne Joy, Veena Menon, Roopa Rachel Paulose, Keechilat Pavithran, Damodaran M Vasudevan
Renata Colombo Bonadio, Ana Paula Messias, Otavio Augusto Moreira, Letícia Vecchi Leis, Bruna Zanin Orsi, Laura Testa, Maria del Pilar Estevez-Diz
Bolanle C Adegboyega, Adewumi O Alabi, Adedayo O Joseph, Nwamaka Lasebikan, Luther A Agaga, Kehinde O Ololade, Anthonia C Sowunmi